ACADIA PHARMACEUTICALS INC. Operating Lease, Payments
ACADIA PHARMACEUTICALS INC. (ACAD) reported Operating Lease, Payments of $3.18 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-05
- ACADIA PHARMACEUTICALS INC. operating lease, payments for the quarter ending 2026-06-30 was $3.18M, a 5.83% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. operating lease, payments for the quarter ending 2026-03-31 was $3.05M, a 6.42% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. operating lease, payments for the quarter ending 2025-12-31 was $3.19M, a 24.05% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. operating lease, payments for the quarter ending 2025-09-30 was $3.05M, a 14.34% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. operating lease, payments for fiscal 2025 was $12.11M, a 17.30% increase from fiscal 2024.
- ACADIA PHARMACEUTICALS INC. operating lease, payments for fiscal 2024 was $10.33M, a 9.21% increase from fiscal 2023.
- ACADIA PHARMACEUTICALS INC. operating lease, payments for fiscal 2023 was $9.46M, a 4.11% increase from fiscal 2022.
- ACADIA PHARMACEUTICALS INC. operating lease, payments for fiscal 2022 was $9.08M, a 71.28% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 3 month as first filed | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $3.18M 10-Q · filed 2026-08-05 | $6.24M 10-Q · filed 2026-08-05 | $9.42M derived: sum of 3 quarters · filed 2026-08-05 | $12.47M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $3.05M 10-Q · filed 2026-05-07 | $6.24M derived: sum of 2 quarters · filed 2026-05-07 | $9.30M derived: sum of 3 quarters · filed 2026-05-07 | $12.30M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $3.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.25M derived: sum of 2 quarters · filed 2026-02-26 | $9.25M derived: sum of 3 quarters · filed 2026-08-05 | $12.11M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $3.05M 10-Q · filed 2025-11-06 | $6.05M derived: sum of 2 quarters · filed 2026-08-05 | $8.92M 10-Q · filed 2025-11-06 | $11.49M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $3.00M 10-Q · filed 2026-08-05 | $5.87M 10-Q · filed 2026-08-05 | $8.44M derived: sum of 3 quarters · filed 2026-08-05 | $11.11M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $2.87M 10-Q · filed 2026-05-07 | $5.44M derived: sum of 2 quarters · filed 2026-05-07 | $8.11M derived: sum of 3 quarters · filed 2026-05-07 | $10.79M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $2.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.24M derived: sum of 2 quarters · filed 2026-02-26 | $7.92M derived: sum of 3 quarters · filed 2026-02-26 | $10.33M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $2.67M 10-Q · filed 2025-11-06 | $5.35M derived: sum of 2 quarters · filed 2025-11-06 | $7.75M 10-Q · filed 2025-11-06 | $10.15M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $2.68M 10-Q · filed 2025-08-07 | $5.08M 10-Q · filed 2025-08-07 | $7.48M derived: sum of 3 quarters · filed 2025-08-07 | $9.82M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $2.40M 10-Q · filed 2025-05-08 | $4.80M derived: sum of 2 quarters · filed 2025-05-08 | $7.14M derived: sum of 3 quarters · filed 2025-05-08 | $9.49M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $2.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $4.74M derived: sum of 2 quarters · filed 2025-02-27 | $7.09M derived: sum of 3 quarters · filed 2025-02-27 | $9.46M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $2.34M 10-Q · filed 2024-11-07 | $4.69M derived: sum of 2 quarters · filed 2024-11-07 | $7.06M 10-Q · filed 2024-11-07 | $9.42M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $2.35M 10-Q · filed 2024-08-07 | $4.72M 10-Q · filed 2024-08-07 | $7.08M derived: sum of 3 quarters · filed 2024-08-07 | $9.38M derived: sum of 4 quarters · filed 2024-08-07 | |
| 2023-03-31 | $2.37M 10-Q · filed 2024-05-09 | $4.73M derived: sum of 2 quarters · filed 2024-05-09 | $7.03M derived: sum of 3 quarters · filed 2024-05-09 | $9.31M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $2.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $4.66M derived: sum of 2 quarters · filed 2024-02-28 | $6.94M derived: sum of 3 quarters · filed 2024-02-28 | $9.08M 10-K · filed 2024-02-28 | |
| 2022-09-30 | $2.29M 10-Q · filed 2023-11-03 | $4.58M derived: sum of 2 quarters · filed 2023-11-03 | $6.72M 10-Q · filed 2023-11-03 | $8.65M derived: sum of 4 quarters · filed 2023-11-03 | |
| 2022-06-30 | $2.29M 10-Q · filed 2023-08-03 | $4.43M 10-Q · filed 2023-08-03 | $6.36M derived: sum of 3 quarters · filed 2023-08-03 | $8.07M derived: sum of 4 quarters · filed 2023-08-03 | |
| 2022-03-31 | $2.19M 10-Q · filed 2023-05-08 | $4.07M derived: sum of 2 quarters · filed 2023-05-08 | $5.78M derived: sum of 3 quarters · filed 2023-05-08 | $6.48M derived: sum of 4 quarters · filed 2023-05-08 | |
| 2021-12-31 | $1.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $3.59M derived: sum of 2 quarters · filed 2023-02-28 | $4.29M derived: sum of 3 quarters · filed 2023-02-28 | $5.30M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $1.71M 10-Q · filed 2022-11-03 | $2.41M derived: sum of 2 quarters · filed 2022-11-03 | $3.42M 10-Q · filed 2022-11-03 | $4.19M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | $696.00K 10-Q · filed 2022-08-09 | $1.71M 10-Q · filed 2022-08-09 | $2.48M derived: sum of 3 quarters · filed 2022-08-09 | $3.61M derived: sum of 4 quarters · filed 2022-08-09 | |
| 2021-03-31 | $1.01M 10-Q · filed 2022-05-05 | $1.78M derived: sum of 2 quarters · filed 2022-05-05 | $2.91M derived: sum of 3 quarters · filed 2022-05-05 | $4.20M derived: sum of 4 quarters · filed 2022-05-05 | |
| 2020-12-31 | $770.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $1.90M derived: sum of 2 quarters · filed 2022-03-01 | $3.19M derived: sum of 3 quarters · filed 2022-03-01 | $4.48M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $1.13M 10-Q · filed 2021-11-09 | $2.42M derived: sum of 2 quarters · filed 2021-11-09 | $3.71M 10-Q · filed 2021-11-09 | $4.95M derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-06-30 | $1.29M 10-Q · filed 2021-08-05 | $2.58M 10-Q · filed 2021-08-05 | $3.82M derived: sum of 3 quarters · filed 2021-08-05 | $5.06M derived: sum of 4 quarters · filed 2021-08-05 | |
| 2020-03-31 | $1.29M 10-Q · filed 2021-05-06 | $2.53M derived: sum of 2 quarters · filed 2021-05-06 | $3.77M derived: sum of 3 quarters · filed 2021-05-06 | $5.00M derived: sum of 4 quarters · filed 2021-05-06 | |
| 2019-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $2.48M derived: sum of 2 quarters · filed 2021-02-25 | $3.71M derived: sum of 3 quarters · filed 2021-02-25 | $4.84M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $1.24M 10-Q · filed 2020-11-04 | $2.47M derived: sum of 2 quarters · filed 2020-11-04 | $3.60M 10-Q · filed 2020-11-04 | ||
| 2019-06-30 | $1.23M 10-Q · filed 2020-08-06 | $2.36M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $1.10M 10-Q · filed 2020-05-08 | $1.10M 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |